A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

In October 2025, Terns Pharmaceuticals announced strongly positive Phase 1 data for TERN-701 in chronic myeloid leukemia, with a 75% major molecular response rate by 24 weeks and no dose-limiting ...

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the ...

Investing.com -- Terns Pharmaceuticals (NASDAQ:TERN) stock surged 28% Tuesday, extending its two-day gain to 120% following positive clinical data for its TERN-701 treatment in relapsed/refractory ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Ascentage Pharma Group International (($HK:6855)) announced an update on their ongoing clinical study. Study Overview: Ascentage Pharma Group Inc.

The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...